On the one hand, NRF2’s unique antioxidant mechanism contributes to radiotherapy resistance, and on the other hand, NRF2 promotes EMT in ESCC cells, facilitated by the infiltration of a large number of macrophage M2, leading to metastasis, tumor progression, and reduced sensitivity to radiotherapy. This evidence concerns the gene NFE2L2 and neoplasm.